TY - JOUR
T1 - Pharmacogenomic testing for mental health (Part II)
T2 - Qualitative analysis of early adopter prescriber perceptions
AU - Manzor Mitrzyk, Beatriz
AU - Plegue, Melissa A.
AU - Kadri, Reema
AU - Danak, Shivang U.
AU - Hubbard, Joseph D.
AU - Kaip, Emily A.
AU - Roberson, Dana N.
AU - Roy, Souvik
AU - Guetterman, Timothy C.
AU - Ellingrod, Vicki L.
AU - Farris, Karen B.
AU - Ruffin Iv, MacK T.
AU - Klinkman, Michael S.
AU - Buis, Lorraine R.
N1 - Funding Information:
This research was funded by Progenity, Inc.; however, Progenity Inc. had no control or influence over data collection, analysis or the drafting of this manuscript. This study was also funded by MCubed, which is part of the University of Michigan’s Third Century Initiative, established by the offices of the President and Provost, and housed in the University of Michigan’s Office of Research (UMOR). LR Buis is obliged to disclose a conflict of interest, as her spouse is an employee and stock holder at Progenity. MT Ruffin is supported by The Hershey Company Professorship and the Dr. And Mrs. Forney P. George Fellowship. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.
Publisher Copyright:
© 2021 Future Medicine Ltd
PY - 2021/5
Y1 - 2021/5
N2 - Aim: We sought to explore how early adopters use pharmacogenomic (PGx) testing for treating depression and attention-deficit/hyperactivity disorder. Patients & methods: Prescribers of the Informed PGx (Progenity, Inc., Ann Arbor, MI 48108, USA) test completed a phone survey assessing use of PGx testing for different scenarios. We conducted a qualitative thematic text analysis of transcribed audio recordings of open-ended responses (n = 62). Results: PGx testing was used when treating multiple comorbidities or resistant disease, and to ease patients' concerns with future therapy. Use of PGx testing is influenced by insurance coverage, interpretability of results and results turnaround time. Conclusion: Prescribers used PGx tests to modify medications for complex patients with depression, attention-deficit/hyperactivity disorder and other disorders to alleviate concerns related to adverse effects and lack of effectiveness.
AB - Aim: We sought to explore how early adopters use pharmacogenomic (PGx) testing for treating depression and attention-deficit/hyperactivity disorder. Patients & methods: Prescribers of the Informed PGx (Progenity, Inc., Ann Arbor, MI 48108, USA) test completed a phone survey assessing use of PGx testing for different scenarios. We conducted a qualitative thematic text analysis of transcribed audio recordings of open-ended responses (n = 62). Results: PGx testing was used when treating multiple comorbidities or resistant disease, and to ease patients' concerns with future therapy. Use of PGx testing is influenced by insurance coverage, interpretability of results and results turnaround time. Conclusion: Prescribers used PGx tests to modify medications for complex patients with depression, attention-deficit/hyperactivity disorder and other disorders to alleviate concerns related to adverse effects and lack of effectiveness.
UR - http://www.scopus.com/inward/record.url?scp=85104591942&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85104591942&partnerID=8YFLogxK
U2 - 10.2217/pme-2020-0084
DO - 10.2217/pme-2020-0084
M3 - Article
C2 - 33728996
AN - SCOPUS:85104591942
SN - 1741-0541
VL - 18
SP - 233
EP - 240
JO - Personalized Medicine
JF - Personalized Medicine
IS - 3
ER -
